Search CTL/CD8+ T-Cell Epitope Database

Found 8 matching records:

Displaying record number 53629

Download this epitope record as JSON.

HXB2 Location	Gag(19-27) p17(19-27) DNA(844..870)	Gag Epitope Map
Author Location	p17(19-27)
Epitope	`IRLRPGGKK`	Epitope Alignment
		Show epitope variants
Species (MHC/HLA)	human(B27)
Immunogen	HIV-1 infection
Patient MHC/HLA	A1, A3, B35, B8
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART, escape, variant cross-reactivity

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
The dominant viral sequence was irlrpggRk, found in 12/15 clones, while the screening sequence IRLRPGGKK was found in 3/15 clones. The least frequent variant stimulated the strongest response.
IRLRPGGKK was previously characterized as a B27 optimized epitope, which is a mismatch with patient's HLA.

References

Casazza2005a Joseph P. Casazza, Michael R. Betts, Brenna J. Hill, Jason M. Brenchley, David A. Price, Daniel C. Douek, and Richard A. Koup. Immunologic Pressure within Class I-Restricted Cognate Human Immunodeficiency Virus Epitopes during Highly Active Antiretroviral Therapy. J. Virol., 79(6):3653-3663, Mar 2005. PubMed ID: 15731259. Show all entries for this paper.

Displaying record number 53633

Download this epitope record as JSON.

HXB2 Location	Gag(20-28) p17(20-28) DNA(847..873)	Gag Epitope Map
Author Location	p17(20-28)
Epitope	`RLRPGGKKK`	Epitope Alignment
		Show epitope variants
Species (MHC/HLA)	human(A3, A30, B42, B62)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, A31, B51, B58w4
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART, escape, variant cross-reactivity

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
The majority of viral sequences prior to therapy were rlrpggkkQ. At week 14 of therapy a major change in the viral quasispecies occurred: the variants present were found to be rlrpggkkK (14/16 clones) and rlrpggkkR (2/16 clones), both well recognized by HIV-specific CD8 T cells. At week 19, the quasispecies reverted back to the less well-recognized rlrpggkkQ variant.
The responses to RLRPGGKKK, RLRPGGKKR, and RLRPGGKKQ were 0.09, 0.11, and 0.02%, respectively.

References

Displaying record number 53631

Download this epitope record as JSON.

HXB2 Location	Gag(20-29) p17(20-29) DNA(847..876)	Gag Epitope Map
Author Location	p17(20-29)
Epitope	`RLRPGGKKKY`	Epitope Alignment
Species (MHC/HLA)	human(A3, A30, B42, B62)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, A3, B44, B7
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
The epitope RLRPGGKKKY was invariant (18/18 sequences) prior to therapy in the patient that recognized it.

References

Displaying record number 53627

Download this epitope record as JSON.

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location	p17(77-85)
Epitope	`SLYNTVATL`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, A2, B44, B70; A2, A31, B51, B58w4
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
This epitope was recognized in 2 individuals and was invariant in both prior to HAART (20/20 clones in each).

References

Displaying record number 53630

Download this epitope record as JSON.

HXB2 Location	Gag(260-267) p24(128-135) DNA(1567..1590)	Gag Epitope Map
Author Location	p24(128-135)
Epitope	`EIYKRWII`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(B8)
Immunogen	HIV-1 infection
Patient MHC/HLA	A1, A3, B35, B8
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART, escape, variant cross-reactivity

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
Diykrwii sequence was found in 12/17 clones after the initiation of therapy, while eVykrwii sequence was found in 5/17, and the peptide used to initially detect the response was not found, EIYKRWII. The less frequent clone was most often recognized. No dramatic shift towards escape was observed after the initiation of therapy.

References

Displaying record number 53634

Download this epitope record as JSON.

HXB2 Location	Pol(283-290) RT(128-135) DNA(2931..2954)	Pol Epitope Map
Author Location	Pol(295-302)
Epitope	`TAFTIPSI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(B51)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, A31, B51, B58w4
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART, escape, variant cross-reactivity, characterizing CD8+ T cells

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied. This epitope provided the best evidence for apparent immune escape during HAART.
Prior to the initiation of therapy, taftipsT variant was found in 24/24 clones. At week 14 of therapy, this variant was completely replaced with taftipsI. By week 19, a complete replacement occurred again, this time to taftipsM. The change at nucleotide level suggests a stepwise progression from ACA to ATA to ATG.
The taftipsT and taftipsM variants had lower avidity than the taftipsI variant, but this wasn't evident at saturating conditions; only careful titrations revealed the difference. HLA-B51 stabilization studies revealed the increased stabilization with the taftipsI form. Also, CD3 down-regulation was larger in response to taftipsI.
The viral shift to the taftipsM variant during HAART was predicted to have minimal or undetectable effect on drug sensitivity.

References

Displaying record number 53632

Download this epitope record as JSON.

HXB2 Location	Nef(73-82) DNA(9013..9042)	Nef Epitope Map
Author Location	Nef(73-82)
Epitope	`QVPLRPMTYK`	Epitope Alignment
Species (MHC/HLA)	human(A3)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, A3, B44, B7
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART, escape, variant cross-reactivity

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
The epitope QVPLRPMTYK was invariant (18/18 sequences) prior to therapy in the patient that recognized it.

References

Displaying record number 53628

Download this epitope record as JSON.

HXB2 Location	Nef(135-143) DNA(9199..9225)	Nef Epitope Map
Author Location	Nef(135-143)
Epitope	`YPLTFGWCY`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(B18, B35, B49, B53, B7)
Immunogen	HIV-1 infection
Patient MHC/HLA	A3, A31, B18, B39; A1, A3, B35, B8
Country	United States
Experimental methods	Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	HAART, ART, escape, variant cross-reactivity

Notes

Evidence of continued viral evolution during HAART therapy despite low viral load was found in 1/5 patients studied.
A predominant sequence of ypltfgwcF was found in 2 patients (in 11/11 and 15/15 sequences) that cross-recognized the peptide used for screening, YPLTFGWCY. In patient B, CD8 T-cell response of 0.95% was found for the dominant variant, while the response for the screening epitope ypltfgwcy was 0.58%. In patient F, the frequency of response did not differ significantly between the 2 variants. Assays for both patients were done immediately prior to the initiation of therapy.